ADRB2 and chronic obstructive pulmonary disease: Findings from our study provide further evidence that β2AR agonists are associated with reduced risk of PD, which is unlikely explained solely by smoking due to the following reasons: One would expect attenuation in this association after adjustment for education and comorbidity as factors strongly associated with smoking, and after the exclusion of COPD patients.